|
1. A composition consisting of eight capture antibodies, each specifically binding to a different protein selected from the group consisting of Cancer Antigen (CA) 15-3 as set forth in SEQ ID NO: 1, CA 19-9 as set forth in SEQ ID NO: 3, Cyclin Dependent Kinase Inhibitor 2D (CDKN2D) as set forth in SEQ ID NO: 6, cysteine rich angiogenic inducer 61 (CYR61) as set forth in SEQ ID NO: 4, Estrogen Receptor (ER) alpha as set forth in SEQ ID NO: 8, Human Epidermal Growth Factor Receptor 2 (HER2) as set forth in SEQ ID NO: 10, progesterone receptor (PR) as set forth in SEQ ID NO: 12, and Vascular endothelial growth factor (VEGF) as set forth in SEQ ID NO: 14, wherein each of the eight capture antibodies is covalently conjugated to a substrate comprising a plurality of dye-conjugated paramagnetic carboxylated beads that are at least 80% monomeric, wherein each or a combination of one, two or three of the eight antibodies is covalently conjugated to the same bead to form one or more sets of beads in the plurality, wherein each set of beads comprises two, three, four or more fluorescent dyes, which provide unique identifiers for the bead set, and wherein the composition panel is capable of simultaneously capturing the eight proteins consisting of CA15-3 of SEQ ID NO: 1, CA 19-9 of SEQ ID NO: 3, CDKN2D of SEQ ID NO: 6, CYR61 of SEQ ID NO: 4, ER of SEQ ID NO: 8, HER2 of SEQ ID NO: 10, PR of SEQ ID NO: 12, and VEGF of SEQ ID NO: 14, from a serum or plasma biological sample obtained from a stage 0 or stage 1 breast cancer patient, in a single plex or multiplex assay for detection and quantification.
|